BioCentury | Jun 11, 2012
Clinical News

ME-143: Phase I data

...and nausea. Data were presented at the American Society of Clinical Oncology meeting in Chicago. Marshall Edwards...
...in combination with platinum-based chemotherapy for an undisclosed type of refractory solid tumors in 4Q12. Marshall Edwards...
...from Novogen under a 2010 deal (see BioCentury, Jan. 3, 2011 & May 16, 2011). Marshall Edwards Inc....
BioCentury | Jun 11, 2012
Finance

Aches for Achillion

...BiovaxID vaccine led to median PFS of 24 months and median OS of 104 months Marshall Edwards Inc....
BioCentury | Jun 4, 2012
Clinical News

ME-344: Phase I started

...of ME-344 on days 1, 2, 8, 9, 15 and 16 of a 28-day cycle. Marshall Edwards Inc....
BioCentury | May 21, 2012
Financial News

Marshall Edwards completes rights offering of units

Marshall Edwards Inc. (NASDAQ: MSHL), San Diego, Calif. Business: Cancer Date completed: 5/14/12 Type: Rights offering of units Raised: $5.2 million Units: 11.7 million Price: $0.45 (unit) Shares after offering: 20.5 million Investors: Existing investors...
BioCentury | Apr 16, 2012
Clinical News

ME-344: Phase I start

...Next month, Marshall Edwards will begin an open-label, dose-escalation Phase I trial to evaluate once-weekly 1.2, 2.5...
...once-weekly 1.2, 2.5, 5, 10 and 20 mg/kg IV ME-344 in up to 24 patients. Marshall Edwards Inc....
BioCentury | Mar 26, 2012
Financial News

Marshall Edwards amends rights offering of units

...Shares: 17.1 million Price: $0.45 (unit) Shares outstanding prior: 14.7 million Investors: Existing investors Note: Marshall Edwards...
...held. Last month, the company proposed to raise up to $8 million in the offering. Marshall Edwards'...
BioCentury | Feb 27, 2012
Financial News

Marshall Edwards proposes rights offering

...are eligible to purchase one share for every share held. Marshall Edwards Inc. (NASDAQ: MSHL), San Diego, Calif...
...to $8 million Shares outstanding prior: 14.7 million Price prior: $0.92 Investors: Existing investors Note: Marshall Edwards'...
BioCentury | Jan 2, 2012
Financial News

Marshall Edwards completes private placement

Marshall Edwards Inc. (NASDAQ:MSHL), San Diego, Calif. Business: Cancer Date completed: 12/29/11 Type: Private placement Raised: $2 million Shares: 1.9 million Price: $1.03 Shares after offering: 13.8 million Investor: Novogen WIR Staff...
BioCentury | Oct 31, 2011
Company News

Ausio, Marshall Edwards deal

...granted Ausio exclusive, worldwide rights to develop and commercialize isoflavone metabolite equol for non-cancer indications. Marshall Edwards...
...undisclosed manufacturing-related IP from Ausio. Terms were not disclosed. Ausio Pharmaceuticals LLC , Cincinnati, Ohio Marshall Edwards Inc....
BioCentury | Oct 3, 2011
Financial News

Marshall Edwards completes private placement

Marshall Edwards Inc. (NASDAQ: MSHL), San Diego, Calif. Business: Cancer Date completed: 9/28/11 Type: Private placement Raised: $2 million Shares: 1.3 million Price: $1.50 Shares after offering: 11.5 million Investor: Novagen Ltd. WIR Staff...
Items per page:
1 - 10 of 80
BioCentury | Jun 11, 2012
Clinical News

ME-143: Phase I data

...and nausea. Data were presented at the American Society of Clinical Oncology meeting in Chicago. Marshall Edwards...
...in combination with platinum-based chemotherapy for an undisclosed type of refractory solid tumors in 4Q12. Marshall Edwards...
...from Novogen under a 2010 deal (see BioCentury, Jan. 3, 2011 & May 16, 2011). Marshall Edwards Inc....
BioCentury | Jun 11, 2012
Finance

Aches for Achillion

...BiovaxID vaccine led to median PFS of 24 months and median OS of 104 months Marshall Edwards Inc....
BioCentury | Jun 4, 2012
Clinical News

ME-344: Phase I started

...of ME-344 on days 1, 2, 8, 9, 15 and 16 of a 28-day cycle. Marshall Edwards Inc....
BioCentury | May 21, 2012
Financial News

Marshall Edwards completes rights offering of units

Marshall Edwards Inc. (NASDAQ: MSHL), San Diego, Calif. Business: Cancer Date completed: 5/14/12 Type: Rights offering of units Raised: $5.2 million Units: 11.7 million Price: $0.45 (unit) Shares after offering: 20.5 million Investors: Existing investors...
BioCentury | Apr 16, 2012
Clinical News

ME-344: Phase I start

...Next month, Marshall Edwards will begin an open-label, dose-escalation Phase I trial to evaluate once-weekly 1.2, 2.5...
...once-weekly 1.2, 2.5, 5, 10 and 20 mg/kg IV ME-344 in up to 24 patients. Marshall Edwards Inc....
BioCentury | Mar 26, 2012
Financial News

Marshall Edwards amends rights offering of units

...Shares: 17.1 million Price: $0.45 (unit) Shares outstanding prior: 14.7 million Investors: Existing investors Note: Marshall Edwards...
...held. Last month, the company proposed to raise up to $8 million in the offering. Marshall Edwards'...
BioCentury | Feb 27, 2012
Financial News

Marshall Edwards proposes rights offering

...are eligible to purchase one share for every share held. Marshall Edwards Inc. (NASDAQ: MSHL), San Diego, Calif...
...to $8 million Shares outstanding prior: 14.7 million Price prior: $0.92 Investors: Existing investors Note: Marshall Edwards'...
BioCentury | Jan 2, 2012
Financial News

Marshall Edwards completes private placement

Marshall Edwards Inc. (NASDAQ:MSHL), San Diego, Calif. Business: Cancer Date completed: 12/29/11 Type: Private placement Raised: $2 million Shares: 1.9 million Price: $1.03 Shares after offering: 13.8 million Investor: Novogen WIR Staff...
BioCentury | Oct 31, 2011
Company News

Ausio, Marshall Edwards deal

...granted Ausio exclusive, worldwide rights to develop and commercialize isoflavone metabolite equol for non-cancer indications. Marshall Edwards...
...undisclosed manufacturing-related IP from Ausio. Terms were not disclosed. Ausio Pharmaceuticals LLC , Cincinnati, Ohio Marshall Edwards Inc....
BioCentury | Oct 3, 2011
Financial News

Marshall Edwards completes private placement

Marshall Edwards Inc. (NASDAQ: MSHL), San Diego, Calif. Business: Cancer Date completed: 9/28/11 Type: Private placement Raised: $2 million Shares: 1.3 million Price: $1.50 Shares after offering: 11.5 million Investor: Novagen Ltd. WIR Staff...
Items per page:
1 - 10 of 80